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In the meantime, it is essential that doctors become more aware
of the risks of the sulfonylurea hypoglycemic drugs and use them
cautiously, when all other therapeutic options have been exhausted.
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Describing Patients With
Discordant Ventriculoarterial Connections
I congratulate Blume et al. (1) on the excellence of their analysis of
patients undergoing the arterial switch operation. I am surprised,
however, when they state that the larger part of their patient group
had “d-transposition,” without providing further definition of this
contentious term. Does this mean, for example, that they excluded
all those patients with complete transposition in which the aorta
was to the left, such as those with mirror-imaged atrial arrange-
ment (transposition {I,L,L})? And did they include those patients
with a congenitally corrected transposition who had right-sided
aortas, such as those with the transposition {I,D,D}? The group
from Boston should now describe the anatomy of their patients
with the same accuracy of analysis which they apply to their results.
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REPLY
We thank Dr. Anderson for his comments. We agree with him
that the importance of anatomic accuracy cannot be overempha-
sized. We did not exclude, on the basis of the spatial relation of the
aortic valve relative to the pulmonary valve, any patient from the
analysis. In fact, the interrelations between the semilunar valves
were specified in the Results section of our report. Furthermore,
we specified that only one patient had transposition of the great
arteries with visceroatrial situs inversus (segmental anatomy
{I,L,L}), and that patient was included in the analysis. We also
specified that patients with physiologically corrected transposition
of the great arteries {S,L,L} were excluded.
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Coronary Endothelial
Dysfunction After Kawasaki Disease
Although the question addressed in the article by Yamakawa et al.
(1) is interesting, there are several issues to be discussed with
respect to the methods and interpretation of the results.
Study protocol. The dose–response curve of normal coronary
arteries to acetylcholine (ACh) in their study is inconsistent with
previously established pharmacologic properties of coronary arter-
ies, on the basis of in vivo and ex vivo data in humans (including
children) and animals (2,3). Although ACh, in fact, dilated normal
epicardial coronary arteries only at high estimated concentrations
(3.0 to 6.0 mmol/liter, estimated final blood concentrations) in
their study, it has been established that ACh does so in a
dose-dependent manner at 0.01 to 1.0 mmol/liter, at which level
the contribution of nitric oxide to ACh-induced response has been
demonstrated (2,3). This difference might be due to the short
infusion time of ACh (30 s) in their study, as compared with 2 to
3 min in other studies. What could be the mechanism of the
ACh-induced vasodilation at 3.0 to 6.0 mmol/liter, but not at 1.0
mmol/liter? In addition, the dose of ACh could be individualized
when it is administered into either right or left coronary arteries in
children of different ages. Because Yamakawa et al. (1) showed
ACh-elicited paradoxic vasoconstriction at 10.0 mmol/liter, the
relatively narrow range of effective ACh concentrations, as com-
pared with those in previous reports, might in fact have produced
highly variable responses to ACh.
Analysis of coronary angiogram. Although Yamakawa et al.
concluded that normal coronary arteries but not regressed aneu-
rysm exhibit a normal ACh response in patients with Kawasaki
disease (KD), the angiograms could be investigated more cau-
tiously. They showed in Figure 3 that normal coronary arteries
after KD (left main coronary artery and distal portion of the left
circumflex artery [LCx]) dilated in response to ACh, whereas the
regressed aneurysm (proximal portion of the left anterior descend-
ing coronary artery [LAD]) constricted. Readers might observe,
however, that other segments (proximal portion of the LCx and
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